Matching articles for "April 7"
Issue 1283 · April 7, 2008 Free
In Brief: Meningococcal Prophylaxis

The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR,…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines ( Med Lett Drugs Ther 2005; 47:29 ) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin ( Cipro , and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin ( Rifadin , and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone ( Rocephin , and others) 250 mg (125 mg for children), or a single oral dose of azithromycin ( Zithromax , and others) 500 mg (10 mg/kg for children) are reasonable alternatives. Download U.S. English
Issue 1283 · April 7, 2008
Simcor: A Niacin/Simvastatin Combination

The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin ( Niaspan ) with a generic statin. Niaspan/simvastatin ( Simcor - Abbott) is approved for use in patients with…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25-6
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin ( Niaspan ) with a generic statin. Niaspan/simvastatin ( Simcor - Abbott) is approved for use in patients with hypercholesterolemia or mixed dyslipidemia (high LDL-cholesterol, low HDL-cholesterol and high serum triglycerides). Niaspan /lovastatin ( Advicor ) was marketed previously for the same indications.
Issue 1283 · April 7, 2008
Nilotinib (Tasigna) for CML

Nilotinib ( Tasigna - Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):26-7
Nilotinib ( Tasigna - Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia (CML) in patients resistant to or intolerant of imatinib ( Gleevec ).
Issue 1283 · April 7, 2008
Tadalafil (Cialis) Once a Day for Erectile Dysfunction

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):27-8
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil (Levitra) , the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.